Zacks Investment ResearchFri, 26 Jun 2026 17:00:42 GMTWhat Makes Nuvectis Pharma (NVCT) a New Buy StockNVCT-2.44%
Seeking AlphaMon, 22 Jun 2026 15:12:09 GMTNuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks TranscriptNVCT-2.44%
Zacks Investment ResearchMon, 25 May 2026 14:56:06 GMTWall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a BetNVCT-2.44%
Zacks Investment ResearchThu, 07 May 2026 14:55:33 GMTWall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to TradeNVCT-2.44%
